JP2021522237A5 - - Google Patents

Info

Publication number
JP2021522237A5
JP2021522237A5 JP2020559365A JP2020559365A JP2021522237A5 JP 2021522237 A5 JP2021522237 A5 JP 2021522237A5 JP 2020559365 A JP2020559365 A JP 2020559365A JP 2020559365 A JP2020559365 A JP 2020559365A JP 2021522237 A5 JP2021522237 A5 JP 2021522237A5
Authority
JP
Japan
Prior art keywords
compound according
nitrogen
ring
partially unsaturated
sulfur
Prior art date
Application number
JP2020559365A
Other languages
English (en)
Japanese (ja)
Other versions
JP7479293B2 (ja
JP2021522237A (ja
JPWO2019209757A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028604 external-priority patent/WO2019209757A1/en
Publication of JP2021522237A publication Critical patent/JP2021522237A/ja
Publication of JP2021522237A5 publication Critical patent/JP2021522237A5/ja
Publication of JPWO2019209757A5 publication Critical patent/JPWO2019209757A5/ja
Priority to JP2023098522A priority Critical patent/JP2023116712A/ja
Application granted granted Critical
Publication of JP7479293B2 publication Critical patent/JP7479293B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559365A 2018-04-24 2019-04-23 プテリジノン化合物およびその使用 Active JP7479293B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023098522A JP2023116712A (ja) 2018-04-24 2023-06-15 プテリジノン化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661744P 2018-04-24 2018-04-24
US62/661,744 2018-04-24
PCT/US2019/028604 WO2019209757A1 (en) 2018-04-24 2019-04-23 Pteridinone compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023098522A Division JP2023116712A (ja) 2018-04-24 2023-06-15 プテリジノン化合物およびその使用

Publications (4)

Publication Number Publication Date
JP2021522237A JP2021522237A (ja) 2021-08-30
JP2021522237A5 true JP2021522237A5 (https=) 2022-04-22
JPWO2019209757A5 JPWO2019209757A5 (https=) 2022-04-22
JP7479293B2 JP7479293B2 (ja) 2024-05-08

Family

ID=66655428

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020559365A Active JP7479293B2 (ja) 2018-04-24 2019-04-23 プテリジノン化合物およびその使用
JP2023098522A Pending JP2023116712A (ja) 2018-04-24 2023-06-15 プテリジノン化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023098522A Pending JP2023116712A (ja) 2018-04-24 2023-06-15 プテリジノン化合物およびその使用

Country Status (11)

Country Link
US (3) US11059826B2 (https=)
EP (1) EP3784669B1 (https=)
JP (2) JP7479293B2 (https=)
CN (1) CN112218865B (https=)
AR (1) AR114828A1 (https=)
AU (1) AU2019257651B2 (https=)
CA (1) CA3097774A1 (https=)
ES (1) ES2969982T3 (https=)
IL (1) IL278122B2 (https=)
TW (1) TWI884914B (https=)
WO (1) WO2019209757A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2969982T3 (es) * 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
PL3919491T3 (pl) * 2019-01-29 2025-10-20 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Inhibitor akt
EP4045498B1 (en) * 2019-10-14 2025-12-03 The Regents of the University of California Broad spectrum anti-cancer compounds
US20230322767A1 (en) 2020-07-29 2023-10-12 Bayer Aktiengesellschaft Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof
CN117088877A (zh) * 2020-10-28 2023-11-21 杭州阿诺生物医药科技有限公司 一种高活性Wnt通路抑制剂化合物
TW202334157A (zh) * 2022-01-29 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 一種Wnt通路抑制劑化合物
TW202333697A (zh) * 2022-01-30 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 Wnt通路抑制劑化合物
CN114436918B (zh) * 2022-02-23 2023-05-23 郑州大学 环丁-1-烯胺类化合物及其制备方法和在药物中的应用
CN117396482B (zh) * 2022-07-28 2026-02-27 杭州阿诺生物医药科技有限公司 一种Wnt通路抑制剂化合物
WO2024022365A1 (zh) * 2022-07-28 2024-02-01 杭州阿诺生物医药科技有限公司 一种Wnt通路抑制剂化合物
US20240217951A1 (en) * 2022-09-23 2024-07-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
PT1427730E (pt) 2001-09-04 2006-11-30 Boehringer Ingelheim Pharma Novas di-hidropteridinonas, processo para sua preparação e sua utilização como medicamento
US6806272B2 (en) * 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
CN1832939B (zh) 2003-05-30 2010-04-28 杰明X医药品加拿大公司 用于治疗癌症或病毒病的三杂环化合物、组合物和方法
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
AU2011226830A1 (en) * 2004-08-14 2011-10-13 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
WO2007014838A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US8865716B2 (en) 2012-02-23 2014-10-21 Boehringer Ingelheim International Gmbh Dihydropteridinones II
JP6052527B2 (ja) 2013-02-21 2016-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノンi
EP2958918B1 (en) 2013-02-21 2016-12-07 Boehringer Ingelheim International GmbH Dihydropteridinones ii
WO2015117055A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
WO2015193229A1 (de) 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe
US10702527B2 (en) * 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN105801582A (zh) * 2016-04-12 2016-07-27 合肥工业大学 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途
ES2969982T3 (es) * 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos

Similar Documents

Publication Publication Date Title
JP2021522237A5 (https=)
JPWO2019209757A5 (https=)
JP2019520417A5 (https=)
CN109415387B (zh) 精氨酸酶抑制剂及其治疗应用
JP2019518768A5 (https=)
JP2016513130A5 (https=)
BR112020008836A2 (pt) Moduladores da via de estresse integrada
JP2021515010A5 (https=)
JP2016509047A5 (https=)
JP2019524665A5 (https=)
WO2018013597A4 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
RU2016126503A (ru) Аналоги кортистатина, их синтез и применения
JPWO2020033828A5 (https=)
JP7611154B2 (ja) ピリド-ピリミジニル化合物及び使用の方法
AR073404A1 (es) Anticuerpos anti-receptor il-6, composiciones que los contienen y metodos para producirlos
JP2021522242A5 (https=)
JP2019529444A5 (https=)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
RU2014121205A (ru) Производные азолов
RU2017104856A (ru) Функционализированные и замещенные индолы в качестве противораковых средств
EA201592287A1 (ru) Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения
RU2013136895A (ru) Новое бициклическое соединение или его соль
JP2017537886A5 (https=)
RU2013136861A (ru) Новое производное индола или индазола или его соль
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.